Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China

Br J Pharmacol. 2024 Mar 21. doi: 10.1111/bph.16342. Online ahead of print.

Abstract

Liver disease constitutes a significant global health concern, particularly in China where it has distinctive characteristics. China grapples with a staggering 300 million cases, predominantly due to hepatitis B and metabolic non-alcoholic fatty liver disease. Additionally, hepatocellular carcinoma has become a prevalent which is a lethal type of cancer. Despite the scarcity of innovative treatment options, Chinese hepatologists and researchers have achieved notable breakthroughs in the prevention, diagnosis, management and treatment of liver diseases. Traditional Chinese medicines have found widespread application in the treatment of various liver ailments owing to their commendable pharmacological efficacy and minimal side effects. Furthermore, there is a growing body of research in extracellular vesicles, cell therapy and gene therapy, offering new hope in the fight against liver diseases. This paper provides a comprehensive overview of the epidemiological characteristics of liver diseases and the diverse array of treatments that Chinese scholars and scientists have pursued in critical field.

Keywords: chronic inflammatory diseases; extracellular vesicles; hepatic; hepatic metabolic diseases; innovative pharmacotherapy; traditional Chinese medicines.

Publication types

  • Review